My LFT is slightly high, but I feel fine”: Doctors explain when borderline liver reports turn dangerous and what should be the immediate preventive measures

LFT slightly high. There is no pain. No yellowing of the eyes. No weakness. So it is easy to brush it aside. But the liver ...
PharmiWeb

Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1)

FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...
Healio

Studies support single-tablet HIV regimen vs. common, complex regimens

Data from two studies presented at the Conference on Retroviruses and Opportunistic Infections support the use of a novel, ...
Pharmabiz

GSK’s bepirovirsen accepted for regulatory review in Japan as a potential first-in-class treatment for chronic hepatitis B

GSK’s bepirovirsen accepted for regulatory review in Japan as a potential first-in-class treatment for chronic hepatitis B: London, UK Friday, February 27, 2026, 09:00 Hrs [IST] ...
The American Journal of Managed Care

Novel Therapies, Long-Acting Antivirals Highlight Oral Abstract Presentation

EMBRACE reported 12-month suppression rates of 94% (IV N6LS+CAB LA), 82% (SC), and 88% (oral SOC), with no virologic failures and no new clinically significant AEs after month 6. Presentations focused ...

Mirum (MIRM) Q4 2025 Earnings Call Transcript

HDV (Hepatitis delta virus): A rare form of viral hepatitis requiring hepatitis B for replication and associated with severe liver disease.

Can Liver Cancer Return After Surgery? A Doctor’s Guide To Recurrence, Risks And Warning Signs

Studies show that up to 50% of patients may experience recurrence within two to three years after curative surgery. By five ...

NanoViricides President Dr. Diwan Interviewed by Mission Matters’ Adam Torres

SHELTON, CONNECTICUT / ACCESS Newswire / February 2, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a ...

MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides

SHELTON, CONNECTICUT / ACCESS Newswire / February 12, 2026 / NanoViricides, Inc., a publicly traded company (NYSE ...

Atea Pharmaceuticals, Inc.: Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026

Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus Initiation of Phase 1 Clinical Program Anticipated Mid-2026 BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuti ...

Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026

Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus Initiation of Phase 1 Clinical Program Anticipated ...

Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2025.